

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
12 June 2025 (12.06.2025)



(10) International Publication Number
WO 2025/120085 A1

(51) International Patent Classification:

A61K 47/68 (2017.01) *A61K 47/64* (2017.01)
A61K 47/60 (2017.01) *A61P 35/00* (2006.01)
A61K 47/61 (2017.01)

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2024/084925

(22) International Filing Date:

05 December 2024 (05.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23214774.4 06 December 2023 (06.12.2023) EP

(71) Applicant: **HEIDELBERG PHARMA RESEARCH GMBH** [DE/DE]; Gregor-Mendel-Str. 22, 68526 Ladenburg (DE).

(72) Inventors: **MÜLLER, Christoph**; c/o Heidelberg Pharma Research GmbH, Gregor-Mendel-Str. 22, 68526 Ladenburg (DE). **GRUSS, Hendrik**; c/o Heidelberg Pharma Research GmbH, Gregor-Mendel-Str. 22, 68526 Ladenburg (DE). **HECHLER, Torsten**; c/o Heidelberg Pharma Research GmbH, Gregor-Mendel-Str. 22, 68526 Ladenburg (DE). **PETRICH, Valentin**; c/o Heidelberg Pharma Research GmbH, Gregor-Mendel-Str. 22, 68526 Ladenburg (DE).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*



WO 2025/120085 A1

(54) Title: MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES

(57) Abstract: The present invention relates to modular linker compounds for target-binding drug conjugates (TBDCs) and in particular to modular linker compounds for antibody-drug-conjugates (ADCs). The modular linker compounds comprise solubility enhancing groups and self-immolative spacers. The invention further relates to methods of synthesizing the modular linker compound, to target-binding drug conjugates comprising the modular linker compound of the invention as well as to pharmaceutical compositions comprising target-binding drug conjugates compound of the invention. Embodiments of the invention have been particularly developed as target-binding drug conjugates for use in the treatment of cancer and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.